Oxbow Advisors’s GeneDx Holdings WGS Stock Holding History

Oxbow Advisors’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-924	Closed	-$11.1K	–	218
2023 Q1	$11.1K	Hold	924	–	–	﹤0.01%	199
2022 Q4	$8.05K	Hold	924	–	–	﹤0.01%	210
2022 Q3	$27K	Hold	924	–	–	﹤0.01%	241
2022 Q2	$38K	Hold	924	–	–	0.01%	252
2022 Q1	$94K	Hold	924	–	–	0.01%	260
2021 Q4	$136K	Hold	924	–	–	0.01%	269
2021 Q3	$231K	Buy	+924	New	+$317K	0.02%	256

Other funds holding WGS

Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Oxbow Advisors's WGS Position: Q2 2023 in Review

Oxbow Advisors sold out of GeneDx Holdings (WGS) in Q2 2023, closing a stake of 924 shares — an estimated $11.1K sold.

Oxbow Advisors first reported a position in WGS in Q3 2021 and held it in 7 quarters. The position peaked at $231K in Q3 2021. 58 funds tracked by Wall St. Rank hold WGS as of Q2 2023.

Oxbow Advisors reported no remaining GeneDx Holdings position as of Q2 2023 after selling out during the quarter.
Oxbow Advisors sold 924 GeneDx Holdings shares in Q2 2023, an estimated $11.1K.
Oxbow Advisors first reported a position in GeneDx Holdings in Q3 2021 and held it in 7 quarters.
Oxbow Advisors's GeneDx Holdings position peaked at $231K in Q3 2021.
58 funds tracked by Wall St. Rank held GeneDx Holdings as of Q2 2023.

Based on Oxbow Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.